Loading
A phase 3 trial of Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by NRG Oncology, active and no longer recruiting.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial is a phase 3 interventional study registered as NCT04513717 by NRG Oncology, with 2753 participants planned, started 2021-01-21 and due to reach its primary completion in 2033-12-31. Interventions recorded: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin. Conditions recorded: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8.
Linked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Buserelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
Shares Histrelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
Shares Relugolix, Degarelix, Triptorelin, Bicalutamide and the tag pipeline.
Shares Relugolix, Degarelix, Triptorelin, Apalutamide and the tag pipeline.
Shares Buserelin, Flutamide, Triptorelin, Bicalutamide and the tag pipeline.
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Flutamide, Bicalutamide, NRG Oncology, Localised prostate cancer, high and very high risk and the tag pipeline.